Unternehmensprofil · Healthcare

Pfizer Inc

PFE · USA
Börse
USA
Land / Region
USA
Börsengang
22. Juni 1942
Mitarbeiter
75.000
Aktueller Kurs
$25.21
Live · 18. Juni 2026
Baillie-Wachstumsscore
40/100
Eher schwach
Innerer Wert · Drei-Stufen-Bereich Aktueller Kurs $25.21 Live · Innerhalb des fairen Bereichs des inneren Werts

Zusammengesetzter Bewertungsbereich · konservativ $16–$19 / fair $24–$28 / optimistisch $32–$36. Bei $25.21, Innerhalb des fairen Bereichs des inneren Werts.

Bei Veröffentlichung $25.85 (25. Mai 2026)

Noch keine Analysen zu dieser Aktie in Ihrer Sprache.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Marktkapitalisierung147,73 Mrd. $
Umsatz (TTM)63,32 Mrd. $
EBITDA25,46 Mrd. $
Nettomarge11,83 %
ROE8,31 %
KGV (TTM)19,79
Erwartetes KGV8,79
PEG3,77
EPS1,31 $
Dividendenrendite6,61 %
52-Wochen-Spanne21,97 $ – 28,28 $
Analysten-Kursziel29,19 $
Analystenbewertung3.6 / 5

Daten von EODHD, dargestellt in der Berichtswährung; nur zu Informationszwecken, keine Anlageberatung.

Geschichte

DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.

Branchenposition

DemnächstDieser Abschnitt wird gerade ergänzt — schauen Sie bald wieder vorbei.